Canaccord lowered the firm’s price target on Intellia Therapeutics (NTLA) to $48 from $54 and keeps a Buy rating on the shares. The firm noted that the clinical hold on the MAGNITUDE Ph3 study in ATTR-CM has been lifted. An updated protocol will be implemented and includes enhanced liver monitoring tests (blood draws) and guidance for short-term course of steroids in response to any elevations.
Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on NTLA:
- Intellia Therapeutics price target raised to $15 from $12 at Wells Fargo
- Intellia Therapeutics price target raised to $30 from $25 at H.C. Wainwright
- Intellia Therapeutics price target raised to $28 from $21 at Citizens
- Intellia Therapeutics price target raised to $27 from $26 at Chardan
- Intellia Therapeutics upgraded at William Blair after clinical hold lifted